Cargando…

Regulation of Molecular Targets in Osteosarcoma Treatment

The most prevalent malignant bone tumor, osteosarcoma, affects the growth plates of long bones in adolescents and young adults. Standard chemotherapeutic methods showed poor response rates in patients with recurrent and metastatic phases. Therefore, it is critical to develop novel and efficient targ...

Descripción completa

Detalles Bibliográficos
Autores principales: Celik, Betul, Cicek, Kader, Leal, Andrés Felipe, Tomatsu, Shunji
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9604206/
https://www.ncbi.nlm.nih.gov/pubmed/36293439
http://dx.doi.org/10.3390/ijms232012583
_version_ 1784817755246034944
author Celik, Betul
Cicek, Kader
Leal, Andrés Felipe
Tomatsu, Shunji
author_facet Celik, Betul
Cicek, Kader
Leal, Andrés Felipe
Tomatsu, Shunji
author_sort Celik, Betul
collection PubMed
description The most prevalent malignant bone tumor, osteosarcoma, affects the growth plates of long bones in adolescents and young adults. Standard chemotherapeutic methods showed poor response rates in patients with recurrent and metastatic phases. Therefore, it is critical to develop novel and efficient targeted therapies to address relapse cases. In this regard, RNA interference technologies are encouraging options in cancer treatment, in which small interfering RNAs regulate the gene expression following RNA interference pathways. The determination of target tissue is as important as the selection of tissue-specific promoters. Moreover, small interfering RNAs should be delivered effectively into the cytoplasm. Lentiviral vectors could encapsulate and deliver the desired gene into the cell and integrate it into the genome, providing long-term regulation of targeted genes. Silencing overexpressed genes promote the tumor cells to lose invasiveness, prevents their proliferation, and triggers their apoptosis. The uniqueness of cancer cells among patients requires novel therapeutic methods that treat patients based on their unique mutations. Several studies showed the effectiveness of different approaches such as microRNA, drug- or chemotherapy-related methods in treating the disease; however, identifying various targets was challenging to understanding disease progression. In this regard, the patient-specific abnormal gene might be targeted using genomics and molecular advancements such as RNA interference approaches. Here, we review potential therapeutic targets for the RNA interference approach, which is applicable as a therapeutic option for osteosarcoma patients, and we point out how the small interfering RNA method becomes a promising approach for the unmet challenge.
format Online
Article
Text
id pubmed-9604206
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-96042062022-10-27 Regulation of Molecular Targets in Osteosarcoma Treatment Celik, Betul Cicek, Kader Leal, Andrés Felipe Tomatsu, Shunji Int J Mol Sci Review The most prevalent malignant bone tumor, osteosarcoma, affects the growth plates of long bones in adolescents and young adults. Standard chemotherapeutic methods showed poor response rates in patients with recurrent and metastatic phases. Therefore, it is critical to develop novel and efficient targeted therapies to address relapse cases. In this regard, RNA interference technologies are encouraging options in cancer treatment, in which small interfering RNAs regulate the gene expression following RNA interference pathways. The determination of target tissue is as important as the selection of tissue-specific promoters. Moreover, small interfering RNAs should be delivered effectively into the cytoplasm. Lentiviral vectors could encapsulate and deliver the desired gene into the cell and integrate it into the genome, providing long-term regulation of targeted genes. Silencing overexpressed genes promote the tumor cells to lose invasiveness, prevents their proliferation, and triggers their apoptosis. The uniqueness of cancer cells among patients requires novel therapeutic methods that treat patients based on their unique mutations. Several studies showed the effectiveness of different approaches such as microRNA, drug- or chemotherapy-related methods in treating the disease; however, identifying various targets was challenging to understanding disease progression. In this regard, the patient-specific abnormal gene might be targeted using genomics and molecular advancements such as RNA interference approaches. Here, we review potential therapeutic targets for the RNA interference approach, which is applicable as a therapeutic option for osteosarcoma patients, and we point out how the small interfering RNA method becomes a promising approach for the unmet challenge. MDPI 2022-10-20 /pmc/articles/PMC9604206/ /pubmed/36293439 http://dx.doi.org/10.3390/ijms232012583 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Celik, Betul
Cicek, Kader
Leal, Andrés Felipe
Tomatsu, Shunji
Regulation of Molecular Targets in Osteosarcoma Treatment
title Regulation of Molecular Targets in Osteosarcoma Treatment
title_full Regulation of Molecular Targets in Osteosarcoma Treatment
title_fullStr Regulation of Molecular Targets in Osteosarcoma Treatment
title_full_unstemmed Regulation of Molecular Targets in Osteosarcoma Treatment
title_short Regulation of Molecular Targets in Osteosarcoma Treatment
title_sort regulation of molecular targets in osteosarcoma treatment
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9604206/
https://www.ncbi.nlm.nih.gov/pubmed/36293439
http://dx.doi.org/10.3390/ijms232012583
work_keys_str_mv AT celikbetul regulationofmoleculartargetsinosteosarcomatreatment
AT cicekkader regulationofmoleculartargetsinosteosarcomatreatment
AT lealandresfelipe regulationofmoleculartargetsinosteosarcomatreatment
AT tomatsushunji regulationofmoleculartargetsinosteosarcomatreatment